Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan, quantity: 100 mg (equivalent: sumatriptan succinate, qty 140 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; sodium bicarbonate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - sumatriptan succinate, quantity: 70 mg (equivalent: sumatriptan, qty 50 mg) - tablet, film coated - excipient ingredients: sodium bicarbonate; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; iron oxide red - indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of imigran in the treatment of basilar or hemiplegic migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 139.98 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 69.99 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; triacetin; iron oxide red - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 50 mg - tablet, dispersible - excipient ingredients: sodium lauryl sulfate; purified talc; fumaric acid; crospovidone; microcrystalline cellulose; methacrylic acid copolymer; colloidal anhydrous silica; triethyl citrate; macrogol 6000; saccharin sodium; sodium hydroxide; magnesium stearate; flavour - children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis, acute tonsilitis and impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organism's susceptibility and thus treatment suitability. therapy may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; poloxamer; povidone; maize starch; purified talc; titanium dioxide; magnesium stearate; hyprolose; propylene glycol - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in; acute pharyngitis, tonsillitis, and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; propylene glycol; maize starch; magnesium stearate; povidone; glucose; poloxamer; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: . acute pharyngitis, tonsillitis, sinusitis; . acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia; . skin and skin structure infections; . non-gonoccocal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organisms' susceptibility and thus treatment suitability. therapy with rulide may be initiated before results of these tests are known; once results become available, appropriate therapy should be considered.